1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86.
2. Moller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer. 1995; 60:587–9.
3. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol. 1996; 23:281–91.
4. Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut. 1998; 43 Suppl 1:S35–8.
5. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: World Cancer Research Fund, American Institute for Cancer Research;2007.
6. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008; 19:689–701.
7. Matsukura N, Onda M, Tokunaga A, Yoshiyuki T, Shimizu Y, Nishi K, et al. Simultaneous gastric cancer in monozygotic twins. Cancer. 1988; 62:2430–5.
8. Kinugasa S, Matsuura H, Abe S, Yoshimura H, Tachibana M, Nakamura T, et al. Simultaneous early gastric cancer in identical twins: report of a case. Surg Today. 1996; 26:189–91.
9. Shah SC, McKinley M, Gupta S, Peek RM Jr, Martinez ME, Gomez SL. Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older. Gastroenterology. 2020; 159:1705–14.
10. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015; 52:361–74.
11. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998; 392:402–5.
12. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol. 1993; 5:797–805.
13. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer. 1996; 77:1605–13.
14. Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, et al. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013; 229:621–9.
15. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci U S A. 1995; 92:8813–7.
16. Lien WH, Klezovitch O, Fernandez TE, Delrow J, Vasioukhin V. alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. Science. 2006; 311:1609–12.
17. Jose L. Orgaz VS-M: RhoA. In: Choi S, editor. Encyclopedia of signaling molecules. Cham: Springer; 2018. p. 4681-91.
18. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015; 16:e60–70.
19. Luo X, Maciaszek JL, Thompson BA, Leong HS, Dixon K, Sousa S, et al. Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines. J Med Genet. 2023; 60:568–75.
20. de Assumpcao PB, de Assumpcao PP, Moreira FC, Ribeiro-Dos-Santos A, Vidal AF, Magalhaes L, et al. Incidence of hereditary gastric cancer may be much higher than reported. Cancers (Basel). 2022; 14:6125.
21. Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010; 67:545–54.
22. Sadok A, Marshall CJ. Rho GTPases: masters of cell migration. Small GTPases. 2014; 5:e29710.
23. Shi J, Wu X, Surma M, Vemula S, Zhang L, Yang Y, et al. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 2013; 4:e483.
24. Li Y, Wang J, Zhong W. Regulation and mechanism of YAP/TAZ in the mechanical microenvironment of stem cells (Review). Mol Med Rep. 2021; 24:506.
25. Almodovar-Garcia K, Kwon M, Samaras SE, Davidson JM. ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site. Mol Cell Biol. 2014; 34:1500–11.
26. Samaras SE, Almodovar-Garcia K, Wu N, Yu F, Davidson JM. Global deletion of Ankrd1 results in a wound-healing phenotype associated with dermal fibroblast dysfunction. Am J Pathol. 2015; 185:96–109.
27. Jimenez AP, Traum A, Boettger T, Hackstein H, Richter AM, Dammann RH. The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth. Oncotarget. 2017; 8:88437–52.
28. Saab S, Chang OS, Nagaoka K, Hung MC, Yamaguchi H. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. Am J Cancer Res. 2019; 9:2719–29.
29. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011; 30:1229–40.
30. He L, Lei Y, Hou J, Wu J, Lv G. Implications of the receptor tyrosine kinase Axl in gastric cancer progression. Onco Targets Ther. 2020; 13:5901–11.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74.
32. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014; 46:583–7.
33. Nam S, Kim JH, Lee DH. RHOA in gastric cancer: functional roles and therapeutic potential. Front Genet. 2019; 10:438.
34. Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR. Structural insights into the interaction of ROCKI with the switch regions of RhoA. J Biol Chem. 2004; 279:7098–104.
35. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Wholegenome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014; 46:573–82.
36. Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, et al. Sporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancers. Gastroenterology. 2017; 153:536–49.
37. Manso R, Sanchez-Beato M, Monsalvo S, Gomez S, Cereceda L, Llamas P, et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood. 2014; 123:2893–4.
38. Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, et al. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer. Oncotarget. 2016; 7:81435–51.
39. Yoon C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 2016; 22:971–83.